Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 11/20 | 0.39 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.36 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.36 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.36 |
| ▸ | RRM1 | P23921 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3975670 | 1.00 | EPHX2 (0.39) | EPHX2SLC6A5DPP7MEN1FAAH | |
| SCHEMBL25364547 | 1.00 | EPHX2 (0.39) | EPHX2SLC6A5DPP7MEN1FAAH | |
| SCHEMBL30130875 | 1.00 | EPHX2 (0.39) | EPHX2SLC6A5DPP7MEN1FAAH | |
| Hydrochloric Acid SCHEMBL403392 | 0.99 | SLC6A5 (0.38) | EPHX2SLC6A5DPP7MEN1FAAH | |
| Hydrochloric Acid SCHEMBL20564397 | 0.99 | SLC6A5 (0.38) | EPHX2SLC6A5DPP7MEN1FAAH | |
| Hydrochloric Acid SCHEMBL403391 | 0.99 | SLC6A5 (0.38) | EPHX2SLC6A5DPP7MEN1FAAH | |
| SCHEMBL20699446 | 0.94 | DPP7 (0.42) | DPP7GNAI3GNAO1GNAI1RRM1 | |
| SCHEMBL18148989 | 0.94 | DPP7 (0.42) | DPP7GNAI3GNAO1GNAI1RRM1 | |
| SCHEMBL30130877 | 0.93 | EPHX2 (0.39) | EPHX2SLC6A5DPP7MEN1FAAH | |
| Hydrochloric Acid SCHEMBL3486209 | 0.92 | DPP7 (0.41) | DPP7GNAI3GNAO1GNAI1RRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230263819-A1 | Lipid Composition and Use Thereof for Delivery of a Therapeutically Active Agent to Endothelium | PANTHERNA THERAPEUTICS GMBH (DE) | 2023-08-24 | — | — | US | claimed |
| EP-4226949-A1 | PREPARATION FOR USE IN A METHOD FOR THE TREATMENT AND/OR PREVENTION OF A DISEASE | Pantherna Therapeutics GmbH (DE) | 2023-08-16 | — | — | EP | claimed |
| EP-3865122-A1 | LIPID COMPOSITION AND USE THEREOF FOR DELIVERY OF A THERAPEUTICALLY ACTIVE AGENT TO ENDOTHELIUM | Pantherna Therapeutics GmbH (DE) | 2021-08-18 | — | — | EP | claimed |
| EP-3833786-B1 | RECOMBINANT NUCLEIC ACID CONSTRUCT | PANTHERNA THERAPEUTICS GMBH (DE) | 2023-12-27 | — | — | EP | disclosed |
| US-20230295651-A1 | RECOMBINANT NUCLEIC ACID CONSTRUCT AND USE THEREOF | GMBH, PANTHERNA T (DE) | 2023-09-21 | — | — | US | disclosed |
| US-20230263819-A1 | Lipid Composition and Use Thereof for Delivery of a Therapeutically Active Agent to Endothelium | PANTHERNA THERAPEUTICS GMBH (DE) | 2023-08-24 | — | — | US | disclosed |
| EP-4226949-A1 | PREPARATION FOR USE IN A METHOD FOR THE TREATMENT AND/OR PREVENTION OF A DISEASE | Pantherna Therapeutics GmbH (DE) | 2023-08-16 | — | — | EP | disclosed |
| EP-3865579-A1 | RECOMBINANT NUCLEIC ACID CONSTRUCT AND USE THEREOF | Pantherna Therapeutics GmbH (DE) | 2021-08-18 | — | — | EP | disclosed |
| EP-3865122-A1 | LIPID COMPOSITION AND USE THEREOF FOR DELIVERY OF A THERAPEUTICALLY ACTIVE AGENT TO ENDOTHELIUM | Pantherna Therapeutics GmbH (DE) | 2021-08-18 | — | — | EP | disclosed |
| EP-3865122-A1 | LIPID COMPOSITION AND USE THEREOF FOR DELIVERY OF A THERAPEUTICALLY ACTIVE AGENT TO ENDOTHELIUM | Pantherna Therapeutics GmbH (DE) | 2021-08-18 | — | — | EP | disclosed |
| EP-3608426-A1 | RECOMBINANT NUCLEIC ACID CONSTRUCT | Pantherna Therapeutics GmbH (DE) | 2020-02-12 | — | — | EP | disclosed |
| US-20190038557-A1 | MEANS FOR LUNG SPECIFIC DELIVERY | SILENCE THERAPEUTICS GMBH (DE) | 2019-02-07 | — | — | US | disclosed |
| US-9387262-B2 | Coated lipid complexes and their use | SILENCE THERAPEUTICS GMBH (DE) | 2016-07-12 | — | — | US | disclosed |
| EP-2992902-A1 | LIPID COMPLEXES COATED WITH PEG AND THEIR USES | Silence Therapeutics GmbH (DE) | 2016-03-09 | — | — | EP | disclosed |
| US-20150031752-A1 | COATED LIPID COMPLEXES AND THEIR USE | SILENCE THERAPEUTICS AG (DE) | 2015-01-29 | — | — | US | disclosed |
| CN-101287497-B | Lipid complexes coated with peg and their use | SILENCE THERAPEUTICS AG | 2013-03-06 | — | — | CN | disclosed |
| WO-2006069782-A9 | LIPID COMPLEXES COATED WITH PEG AND THEIR USE | SILENCE THERAPEUTICS AG (DE) | 2009-04-30 | — | — | WO | disclosed |
| CN-101287497-A | Lipid complexes coated with peg and their use | SILENCE THERAPEUTICS AG (DE) | 2008-10-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230263819-A1 | Lipid Composition and Use Thereof for Delivery of a Therapeutically Active Agent to Endothelium | LIPG, SLC27A1, SLC27A2 | EPHX2 2544/4885SLC6A5 2224/4885DPP7 1570/4885 |
| US-20150031752-A1 | COATED LIPID COMPLEXES AND THEIR USE | HDLBP, NR1H3, CETP | EPHX2 305/4885SLC6A5 4838/4885DPP7 2358/4885 |
| US-20190038557-A1 | MEANS FOR LUNG SPECIFIC DELIVERY | SGMS1, SGMS2, DEGS1 | EPHX2 1272/4885SLC6A5 2900/4885DPP7 3363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.